Membrane perturbational effects of antiarrhythmic drugs.
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001950:Bretylium Tosylate / Q000494:pharmacology; D004228:Dithionitrobenzoic Acid / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004910:Erythrocyte Membrane / Q000187:drug effects*; D004912:Erythrocytes / Q000187:drug effects*; D006461:Hemolysis / Q000187:drug effects; D008012:Lidocaine / Q000494:pharmacology; D008563:Membrane Lipids / Q000378:metabolism; D008565:Membrane Proteins / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D011217:Practolol / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011802:Quinidine / Q000494:pharmacology; D014302:Trinitrobenzenesulfonic Acid / Q000378:metabolism
D000889:Anti-Arrhythmia Agents; D008563:Membrane Lipids; D008565:Membrane Proteins; D010743:Phospholipids; D001950:Bretylium Tosylate; D014302:Trinitrobenzenesulfonic Acid; D008012:Lidocaine; D004228:Dithionitrobenzoic Acid; D011433:Propranolol; D011802:Quinidine; D011217:Practolol